Biolidics issues letter of demand to biochip partner Sysmex over IP matters

Singapore

A CATALIST-LISTED medtech firm that made strong gains this year as investors hunted for exposure to tech plays and Covid-19 test makers, has now claimed that a Japanese group breached intellectual property-related (IP) agreements.

Biolidics has issued a letter of demand to Japan-based healthcare group Sysmex Corporation, saying that Sysmex breached IP obligations under a collaboration agreement struck in 2016 for the joint development of biochips.